Seres Therapeutics, Inc. 8-K

What Happened
Seres Therapeutics, Inc. announced in a Form 8-K filed March 16, 2026 that its 2026 annual meeting of stockholders will be held on June 9, 2026. Holders of record of common stock as of the close of business on April 13, 2026 will be entitled to vote. The meeting time and location will be provided in the company’s definitive proxy statement. Because the 2026 meeting is more than 30 days after the anniversary of the 2025 meeting, Seres is providing a revised deadline for shareholder proposals under Rule 14a-8.

Key Details

• 2026 Annual Meeting date: June 9, 2026.
• Record date for voting eligibility: close of business on April 13, 2026.
• Deadline to submit Rule 14a-8 shareholder proposals for inclusion in the proxy: close of business on March 26, 2026 (the 10th day after this 8-K).
• Time and location of the meeting will be disclosed in the company’s definitive proxy statement.

Why It Matters
This notice tells investors when the company’s annual meeting will occur, who may vote, and the cutoffs for submitting shareholder proposals to appear in the company’s proxy materials. Shareholders planning to vote, participate, or submit proposals under Rule 14a-8 should note the record date and the March 26, 2026 proposal deadline so their submissions and voting rights are timely. The definitive proxy will contain full voting instructions and meeting logistics.